News / Blog
May Holidays 2023 - Pay Attention!
Teprenone capsules 50 mg for gastritis and ulcer (Selbex, geranylgeranylacetone)
Product Code :
Availability : 10
General information on Japanese Teprenone capsules 50 mg for gastritis and ulcer (Selbex, geranylgeranylacetone)
Package details: 100 capsules
Manufacturer: Nichi-Iko Pharmaceutical Co., Ltd, Japan
Active ingredient: teprenone (chemical formula C23H38O)
Medical effect: Teprenone capsules are effective for the treatment of following diseases and conditions:
- acute gastritis,
- gastric mucosal lesion, including erosion, bleeding, flare, and edema in acute exacerbation of chronic gastritis,
- gastric ulcer.
Contraindications and precautions: do not use for pregnant or breastfeeding women.
If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration
For adults: take 1 capsule (50 mg of the active ingredient) at a time, 3 times a day, after meals. The doctor in charge may be adjust the dosage according to age or symptoms of the patient.
How effective are Teprenone capsules 50 mg from Japan for gastritis and ulcer (Selbex, geranylgeranylacetone)?
Teprenone is an analog of terpene and an inducer of heat shock proteins. It works by improving blood flow in the gastric mucosa and increasing synthesis and secretion of the components of gastric mucosa. As the result, Teprenone capsuels help to regenerate ulcerated tissue of gastric mucosa.
Who should take Teprenone capsules 50 mg from Japan?
Teprenone capsules are effective for the treatment of gastric ulcer, acute gastritis and gastric mucosal lesion, including erosion, bleeding, flare, and edema, in acute exacerbation of chronic gastritis. Study involving 369 patients showed that teprenone improves gastric mucosal injury and dyspeptic symptoms caused by long-term nonsteroidal anti-inflammatory drug use (Yingying Gong, Xinxin Huang et al. “Teprenone improves gastric mucosal injury and dyspeptic symptoms in long-term nonsteroidal anti-inflammatory drug users” // Journal of Gastroenterology and Hepatology, 2019, 34(8): 1344-1350).